AbbVie Inc. (ABBV)

AbbVie Inc., incorporated in Delaware in 2012, is a global, diversified research-based biopharmaceutical company that became an independent, publicly-traded entity on January 1, 2013, following its spin-off from Abbott Laboratories. The company operates as a single global business segment focused on the research and development, manufacturing, commercialization, and sale of innovative medicines, with a global R&D and supply chain organization supporting products that are commercialized through regionally and therapeutically organized sales efforts. AbbVie holds leadership positions across five key therapeutic areas: immunology, oncology, aesthetics, neuroscience, and eye care.

Its immunology portfolio includes Humira (adalimumab), which treats numerous autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, and accounted for approximately 27% of AbbVie's total net revenues in 2023; Skyrizi (risankizumab), an IL-23 inhibitor for plaque psoriasis, psoriatic arthritis, and Crohn's disease; and Rinvoq (upadacitinib), an oral JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, and Crohn's disease. In oncology, AbbVie markets Imbruvica (ibrutinib) for blood cancers including chronic lymphocytic leukemia, Venclexta/Venclyxto (venetoclax) for CLL and acute myeloid leukemia, Epkinly (epcoritamab) for certain lymphomas, and Elahere (mirvetuximab soravtansine-gynx), an antibody-drug conjugate for ovarian and related cancers under accelerated FDA approval. The Aesthetics segment features market-leading products such as Botox Cosmetic for facial lines, the Juvederm Collection of dermal fillers, and other offerings including Alloderm, CoolSculpting, Natrelle breast implants, SkinMedica, Latisse, and DiamondGlow.

AbbVie's neuroscience portfolio includes Botox Therapeutic for conditions like chronic migraine and spasticity, Vraylar for schizophrenia and bipolar disorder, Duopa/Duodopa for advanced Parkinson's disease, and migraine treatments Ubrelvy and Qulipta (marketed as Aquipta in the EU). Its eye care products address glaucoma, dry eye, and retinal conditions through Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and others such as Refresh/Optive, Xen, and Durysta. Additional key products include Mavyret/Maviret for chronic hepatitis C, Creon for exocrine pancreatic insufficiency, Lupron for prostate cancer and related hormone-driven conditions, Linzess/Constella for irritable bowel syndrome with constipation and chronic idiopathic constipation, and Synthroid for hypothyroidism.

Collectively, AbbVie's diversified portfolio and global commercial infrastructure position it to address complex and serious diseases across multiple therapeutic categories worldwide.